2020

FOR MORE INFORMATION OR TO REGISTER, VISIT: HTTPS://CVENT.ME/Z2L1A?REFID=GA-2.

MARCH 11-15, 2020Fairmont Chateau WhistlerWhistler, BC, Canada

7TH ANNUAL GLOBAL SUMMIT ON

HEMATOLOGIC MALIGNANCIES

JOIN OUR CHAIRS

STEVEN COUTRÉ, MDStanford University School of Medicine

JOSEPH MIKHAEL, MD, MED, FRCPC, FACPTranslational Genomics Research InstituteCity of Hope

RICHARD STONE, MDDana-Farber Cancer InstituteHarvard Medical School

ANDREW ZELENETZ, MD, PHDMemorial Sloan Kettering Cancer CenterWeill Cornell Medical College

CHAIRS

STEVE COUTRE, MDProfessor of Medicine, HematologyStanford University School of MedicineStanford, CA

JOSEPH MIKHAEL, MD, MED, FRCPC, FACPProfessor, Applied Cancer Research and Drug DiscoveryTranslational Genomics Research InstituteCity of HopePhoenix, AZ

RICHARD STONE, MDDirector, Adult Acute Leukemia ProgramDana-Farber Cancer InstituteProfessor of MedicineHarvard Medical SchoolBoston, MA

ANDREW ZELENETZ, MD, PHDMedical Director, Quality InformaticsAttending PhysicianMemorial Sloan Kettering Cancer CenterProfessorWeill Cornell Medical CollegeNew York, NY

JOHN ALLAN, MDAssistant Professor of MedicineDivision of Hematology and Medical OncologyWeill Cornell MedicineNew York, NY

MICHAEL ANDREEFF, MD, PHDProfessor of Medicine and Paul and Mary Haas Chair in GeneticsChief, Molecular Hematology and TherapyDepartments of Leukemia and Stem Cell Transplantation and Cellular TherapyThe University of Texas MD Anderson Cancer CenterHouston, TX

VERONIKA BACHANOVA, MDAssociate Professor of MedicineUniversity of MinnesotaMinneapolis, MN

WILLIAM BENSINGER, MDDirector, Myeloma ProgramMyeloma and Transplant ProgramSwedish Cancer InstituteSeattle, WA

JAMES BERENSON, MDCEO, President, Medical and Scientific DirectorInstitute for Myeloma and Bone Cancer ResearchLos Angeles, CA

PRITHVIRAJ BOSE, MDAssociate ProfessorThe University of Texas MD Anderson Cancer CenterHouston, TX

ELISE CHONG, MDAssistant Professor of MedicineAssociate Director, Lymphoma Clinical Trials Research UnitLymphoma Program, Abramson Cancer CenterUniversity of PennsylvaniaPhiladelphia, PA

ANDREW COWAN, MDAssistant Member, Clinical Research DivisionFred Hutchinson Cancer CenterAssistant Professor of Medicine, Division of Medical OncologyUniversity of Washington School of MedicineSeattle, WA

ALEXEY V. DANILOV, MD, PHDAssociate Professor of MedicineOregon Health and Science University Portland, OR

PINKAL DESAI, MD, MPHAssistant Professor of MedicineWeill Cornell Medical CollegeAssistant Attending PhysicianNew York-Presbyterian HospitalNew York, NY

NAVAL DAVER, MDAssociate ProfessorDepartment of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston, TX

SVEN DE VOS, MD, PHDAssociate ProfessorDavid Geffen School of Medicine at UCLALos Angeles, CA

VARSHA GANDHI, PHDProfessor and Chair, ad interimDepartment of Experimental TherapeuticsThe University of Texas MD Anderson Cancer CenterHouston, TX

BRIAN HILL, MD, PHDDirector, Lymphoid Malignancies ProgramAssociate Professor, Taussig Cancer Institute Cleveland Clinic Cleveland, OH

RONALD HOFFMAN, MDProfessor of MedicineDivision of Hematology and Medical OncologyIcahn School of Medicine at Mount SinaiNew York, NY

NITIN JAIN, MDAssociate Professor of MedicineDepartment of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston, TX

SHAJI KUMAR, MDProfessor of MedicineMayo ClinicRochester, MN

HANS LEE, MDAssistant ProfessorThe University of Texas MD Anderson Cancer CenterHouston, TX

THOMAS MARTIN, MDProfessor of Clinical MedicineUniversity of California, San FranciscoHelen Diller Family Comprehensive Cancer CenterSan Francisco, CA

SOHEIL MESHINCHI, MD, PHDProfessor of MedicineFred Hutchinson Cancer CenterUniversity of Washington School of MedicineSeattle, WA

DAVID MIKLOS, MD, PHDClinical Director of Cancer Cell TherapyAssociate Professor of MedicineStanford UniversityStanford, CA

CLIFTON MO, MDMedical OncologistDana-Farber Cancer InstituteBoston, MA

OMAR NADEEM, MDMedical OncologistJerome Lipper Multiple Myeloma CenterDana-Farber Cancer InstituteInstructor in MedicineHarvard Medical SchoolBoston, MA

LORETTA NASTOUPIL, MDAssociate ProfessorDepartment of Lymphoma/MyelomaThe University of Texas MD Anderson Cancer CenterHouston, TX

JOHN PAGEL, MD, PHDChief of Hematologic MalignanciesDirector of Hematopoietic Stem Cell Transplantation ProgramCenter for Blood Disorders and Stem Cell TransplantationSwedish Cancer InstituteSeattle, WA

KRISH PATEL, MDDirector, Lymphoma ProgramCenter for Blood Disorders and Stem Cell TransplantationSwedish Medical CenterSeattle, WA

NAVEEN PEMMARAJU, MDAssociate Professor, LeukemiaThe University of Texas MD Anderson Cancer CenterHouston, TX

TYCEL PHILLIPS, MDAssistant ProfessorUniversity of Michigan MedicineAnn Arbor, MI

NOOPUR RAJE, MDProfessor of MedicineHarvard Medical SchoolDirector, Center for Multiple Myeloma Massachusetts General HospitalBoston, MA

FARHAD RAVANDI, MDProfessor of MedicineChief, Section of Acute Myeloid LeukemiaThe University of Texas MD Anderson Cancer CenterHouston, TX

DONNA REECE, MD, FRCPCProfessor, Department of MedicineUniversity of TorontoDirector, Program for Multiple Myeloma and Related DiseasePrincess Margaret Cancer CentreToronto, Canada

ASHLEY ROSKO, MDAssociate Professor, Division of HematologyThe James Cancer Hospital Comprehensive Cancer CenterOhio State UniversityColumbus, OH

Wednesday, March 11, 2020

Setting the Stage5:00 pm Welcome and Introductions

5:15 pm Targeting the Mitochondria in B-cell Malignancies

5:30 pm Can We Finally Start Sub-setting DLBCL in 2020?

5:45 pm How Do We Get to the Next Inflection Point in MM?

6:00 pm BREAK

6:30 pm FLT3 Madness: Anarchy in Clinical Trials

6:45 pm What’s New in AML: How to Develop New Drugs in AML

7:00 pm How to Limit the Impact of CLL on Patients’ Lives

7:15 pm PANEL DISCUSSION

8:00 pm ADJOURN TO WELCOME RECEPTION

Thursday, March 12, 2020

Chronic Lymphocytic Leukemia7:00 am CLL Combinations: Is the Whole Greater than the Sum of the Parts?

7:15 am How Can We Overcome the Immunosuppressive Microenvironment in CLL?

7:30 am MRD in CLL: How Deep Should We Go?

7:45 am DISCUSSION

8:00 am Overcoming Primary and Acquired Resistance to BTKi in WM

8:15 am Influence of BTK Inhibitors on Immune Function

8:30 am Updated Results: Next-generation BTKi

8:45 am What are the Next Steps for Ibrutinib in CLL?

9:00 am DISCUSSION

9:30 am BREAK

TENTATIVE AGENDA

FACULTY CONTINUED

9:45 am Update on Murano Data (R/R vs. BR)

10:00 am Venetoclax: Impact of Early Intervention in CLL

10:15 am Emerging Data on PI3K Resistance in CLL

10:30 am PANEL DISCUSSION

Emerging Agent Showcases11:00 am - 12:00 pm Emerging Agents

12:00 pm ADVISORY BOARDS

Debating Technology: Is There a Role for Chemotherapy in CLL?5:00 pm Chemo-free Options: The Future of CLL Treatment

5:10 pm Chemotherapy is Not Dead in CLL

5:20 pm PANEL DISCUSSION

Lymphomas6:00 pm Ibrutinib and Venetoclax in Frontline DLBCL

6:15 pm Polatuzumab in DLBCL

6:30 pm The Role of Non-chemotherapy Options in MCL

6:45 pm Approach to Patients with FL in Early Transformation

7:00 pm Development of Rational Combinations with PI3K in Heme Malignancies

7:15 pm Can Bispecific CAR-T Overcome Challenges with Traditional CAR-T Therapy in DLBCL?

7:30 pm Challenges in Clinical Trial Desgin for CAR-T in R/R DLBCL

7:45 pm PANEL DISCUSSION

8:30 pm ADJOURN TO POSTER RECEPTION

SARAH RUTHERFORD, MDAssistant ProfessorWeill Cornell MedicineNew York, NY

CHARLES SCHIFFER, MDProfessor of MedicineBarbara Ann Karmanos Cancer Institute Detroit, MI

STEPHEN J. SCHUSTER, MDRobert and Margarita Louis-Dreyfus Professor of Chronic Lymphocytic Leukemia and LymphomaDirector, Lymphoma Program and Lymphoma Translational ResearchAbramson Cancer CenterUniversity of PennsylvaniaPhiladelphia, PA

NINA SHAH, MDAssociate ProfessorUniversity of California San FranciscoSan Francisco, CA

DAVID SIEGEL, MD, PHDDirectorMultiple Myeloma InstituteHackensack University Medical CenterHackensack, NJ

EDWARD STADTMAUER, MDSection Chief, Hematologic MalignanciesRoseman, Tarte, Harrow, and Shaffer Families’ President’s Distinguished ProfessorPerelman School of MedicineUniversity of PennsylvaniaPhiladelphia, PA

A. KEITH STEWART, MB, CHBCarlson and Nelson Endowed Director, Center for Individualized Medicine Vasek and Anna Maria Polak Professor of Cancer ResearchProfessor of MedicineMayo ClinicScottsdale, AZ

STEVEN TREON, MD, PHD, FRCP, FACPDirector, Bing Center for Waldenstrom’s MacroglobulinemiaProfessor, Harvard Medical SchoolDana-Farber Cancer InstituteBoston, MA

RAVI VIJ, MD, MBAProfessor of MedicineWashington University School of Medicine in St. LouisSt. Louis, MO

EUNICE S. WANG MDChief, Leukemia ServiceProfessor of OncologyDepartment of MedicineRoswell Park Comprehensive Cancer InstituteBuffalo, NY

ADRIAN WIESTNER, MD, PHDChief, Lymphoid Malignancies SectionNIH National Heart, Lung, and Blood InstituteBethesda, MD

JEFFREY A. ZONDER, MDProfessor of OncologyMultiple Myeloma and Amyloidosis Multidisciplinary Team LeaderKarmanos Cancer InstituteWayne State University School of MedicineDetroit, MI

Friday, March 13, 2020

Multiple Myeloma7:00 am How Many Drugs Do We Need in First-line Myeloma?

7:15 am What’s Next for CAR-T in MM?

7:30 am Ixazomib Maintenance in Newly Diagnosed Multiple Myeloma

7:45 am DISCUSSION

8:15 am Role of Daratumumab in Frontline Multiple Myeloma

8:30 am Understanding Immune Resistance to Daratumumab in Myeloma

8:45 am What Role Will Isatuximab Play in Multiple Myeloma?

9:00 am What is Next with CD38 Antibodies?

9:15 am DISCUSSION

9:45 am BREAK

10:00 am Will Venetoclax Also Be a Multiple Myeloma Drug?

10:15 am Status of Anti-fibril Therapy (Monoclonal Antibodies) in AL Amyloidosis

10:30 am PANEL DISCUSSION

Emerging Agent Showcases10:50 am - 11:30 am Emerging Agents

11:30 am PANEL DISCUSSION

12:00 pm ADVISORY BOARDS

Debating Technology: Future Role of T-cell Engagers (CAR-T vs. Bispecifics)5:00 pm CAR-T: The Technology of the Future

5:10 pm Bi-Tri-specific Antibodies: The Optimal Way to Engage T Cells

5:20 pm PANEL DISCUSSION

Acute Myeloid Leukemia6:00 pm Understanding the Biology of Hereditary AML

6:15 pm Is the Age of 7+3 Coming to an End?

6:30 pm Novel Agents: Beyond JAK Inhibition in Myelofibrosis

6:45 pm Personalized Cancer Vaccines in Heme Malignancies

7:00 pm Single-cell Genomic Analysis in AML

7:15 pm BCL2 Inhibition in AML: The New Standard of Care?

7:30 pm Venetoclax-based Existing and Upcoming Combinations

7:45 pm Increasing Remissions in BPDCN with IL-3 Receptor Targeting and Beyond

8:00 pm Patient Case in 2023: The Future of Treating AML

8:15 pm PANEL DISCUSSION

8:30 pm ADJOURN TO RECEPTION

Saturday, March 14, 2020

Emerging Trends in Lymphoma and CLL7:00 am HCK Inhibition in MYD88 Diseases

7:15 am Novel Targeted Strategies: The Nuclear Pore and Beyond

7:30 am Durability of CAR-T Cell Remissions in Refractory B-cell Lymphomas: How Many People Can We Save and for How Long?

7:45 am Armored CAR-T Cells in R/R NHL and CLL Including Richter’s Transformation

8:00 am DISCUSSION

8:30 am Role of PD-1 and PD-L1 Therapy in Hodgkin’s Lymphoma

8:45 am Incorporating Novel Therapeutics in Hodgkin’s Lymphoma

9:00 am Emerging Data on Bispecific Antibodies in Lymphoma

9:15 am Emerging Role of ADCs in Combination with Chemotherapy for the Treatment of PTCL

9:30 am PANEL DISCUSSION

10:30 am BREAK

Emerging Agent Showcases10:50 am - 11:20 am Emerging Agents

11:20 am PANEL DISCUSSION

12:00 pm ADVISORY BOARDS

Debating Technology: Utilizing Current CAR-T Therapy vs. Optimizing Future CARs5:00 pm Finding a Role for Current CAR-T Technology

5:10 pm Necessity of Optimizing CAR-T Technology

5:20 pm PANEL DISCUSSION

Emerging Trends in Hematologic Malignancies6:00 pm Feasibility of CAR-T Therapy for R/R DLBCL Patients in the Real World

6:15 pm Update on CAR-T Therapy for Lymphoma: Long-term Durability and Prospects for the Future

6:30 pm Armored Monoclonal Antibodies in AML

6:45 pm Identifying Immunogenic Targets in AML

7:00 pm T-cell–based Therapies in AML

7:15 pm DISCUSSION

7:30 pm Role of FLT3 Post-transplant in AML

7:45 pm Future Roles of FLT3 Inhibition as Single-agent and Combination Therapy in AML

8:15 pm Treatment Sequencing in Patients with R/R MM after Daratumumab

8:30 pm Where is Selinexor Going to Fit in the Multiple Myeloma Landscape?

8:45 pm PANEL DISCUSSION

9:15 pm ADJOURN

Sunday, March 15, 2020

Oral Abstracts7:00 am - 8:10 am Oral Abstracts

8:10 am PANEL DISCUSSION

8:30 am ADJOURN

TENTATIVE AGENDA